A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of AMG 334 in Migraine Prevention

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 09 Dec 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

09 Nov 2022 Results of cost effectiveness analysis from NCT02066415, STRIVE, ARISE, LIBERTY and HER-MES presented at the 25th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research
13 Oct 2022 Results of post-hoc analysis of 4 studies (NCT02456740, NCT02066415, NCT02630459, and NCT03812224) assessing consistency of erenumab effect throughout the monthly treatment cycle, published in the Headache.
08 Feb 2022 Results from ARISE and STRIVE assessing the changes in the functional impact of migraine following treatment with erenumab, as measured by the Migraine Functional Impact Questionnaire, published in the Headache.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com